HCC1937Homo sapiens (Human)Cancer cell line
Also known as: HCC-1937, HCC/1937, Hamon Cancer Center 1937, Tom98 (Not really a misspelling but an assignment of a name based on first author of publication and date because assignment of correct cell line name was not done correctly.)
Quick Overview
Human breast cancer cell line with BRCA1 mutation and chromosomal instability.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_0290 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Breast[UBERON:UBERON_0000310] |
Donor Information
| Age | 24 |
|---|---|
| Age Category | Adult |
| Sex | Female |
| Race | caucasian |
| Subtype Features | basal_A TNBC |
Disease Information
| Disease | Breast ductal carcinoma |
|---|---|
| Lineage | Breast |
| Subtype | Breast Invasive Ductal Carcinoma |
| OncoTree Code | IDC |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000223_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| Gene deletion | PTEN | - | Hemizygous | - | Wistar |
| MutationSimple | BRCA1 | p.Gln1756Profs*74 (c.5266dupC) (5382insC) | Unspecified | The breast carcinoma cell line HCC1937 | PubMed=21585244 |
| MutationSimple | RB1 | p.Thr738_Arg775del38 (c.2212_2325del114) | Homozygous | - | from parent cell line HCC1937 |
| MutationSimple | TMPRSS2 | p.Gly8Val (c.23G>T) (c.-57+99G>T) | Heterozygous | - | PubMed=34339474 |
| MutationSimple | TMPRSS2 | p.Val197Met (c.589G>A) (p.Val160Met, c.478G>A) | Homozygous | - | PubMed=34339474 |
| MutationSimple | TP53 | p.Arg306Ter (c.916C>T) | Heterozygous | Germline | PubMed=16418264 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Identification of cell lines CL-14, CL-40 and CAL-51 as suitable models for SARS-CoV-2 infection studies.
Safranko Z.M., Kurolt I.-C., Markotic A., Cicin-Sain L., Steenpass L.
PLoS ONE 16:E0255622-E0255622(2021).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis.
Bedford M.T., Shi X.-B., Li W., Barton M.C., Dent S.Y.R., Kraus W.L.
Genome Res. 28:159-170(2018).
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
Lakhani S.R.
Breast Cancer Res. Treat. 167:289-301(2018).
Glycoproteins in claudin-low breast cancer cell lines have a unique expression profile.
Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.
J. Proteome Res. 16:1391-1400(2017).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
Breast cancer stem cells: tumourspheres and implications for therapy.";
Morrison B.J.
Thesis PhD (2010); Griffith University; Brisbane; Australia.
Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier.
Minna J.D., Gazdar A.F.
Cancer Res. 58:3237-3242(1998).
Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer.
Tomlinson G.E., Tonk V., Ashfaq R., Leitch A.M., Minna J.D., Shay J.W.
Int. J. Cancer 78:766-774(1998).
Comparison of features of human breast cancer cell lines and their corresponding tumors.
Gazdar A.F.
Clin. Cancer Res. 4:2931-2938(1998).
Genetic analysis of BRCA1 function in a defined tumor cell line.";
Livingston D.M.
Mol. Cell 4:1093-1099(1999).
Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.
Minna J.D.
Oncogene 20:1005-1009(2001).
Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene.
Birnbaum D., Chaffanet M.
Genes Chromosomes Cancer 35:204-218(2002).
NBS1 localizes to gamma-H2AX foci through interaction with the FHA/BRCT domain.
Matsuura S., Kobayashi T., Tamai K., Tanimoto K., Komatsu K.
Curr. Biol. 12:1846-1851(2002).
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Edwards P.A.W., Chaffanet M.
Genes Chromosomes Cancer 37:333-345(2003).
High-resolution analysis of DNA copy number using oligonucleotide microarrays.
Weber B., Shapero M.H., Wooster R.
Genome Res. 14:287-295(2004).
Possible causes of chromosome instability: comparison of chromosomal abnormalities in cancer cell lines with mutations in BRCA1, BRCA2, CHK2 and BUB1.
Grigorova M., Staines J.M., Ozdag H., Caldas C., Edwards P.A.W.
Cytogenet. Genome Res. 104:333-340(2004).
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.
Cancer Res. 66:41-45(2006).
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
Breast Cancer Res. Treat. 99:97-101(2006).
The consensus coding sequences of human breast and colorectal cancers.
Vogelstein B., Kinzler K.W., Velculescu V.E.
Science 314:268-274(2006).
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
Cancer Cell 10:515-527(2006).
High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization.
Ringner M., Hoglund M., Borg A.
Genes Chromosomes Cancer 46:543-558(2007).
The genomic landscapes of human breast and colorectal cancers.";
Vogelstein B.
Science 318:1108-1113(2007).
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
Pollack J.R.
PLoS ONE 4:E6146-E6146(2009).
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.
Breast Cancer Res. Treat. 121:53-64(2010).
Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.
Yamamoto S., Oka M., Hirano T., Sasaki K.
BMC Cancer 10:15.1-15.10(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.
Chavez K.J., Garimella S.V., Lipkowitz S.
Breast Dis. 32:35-48(2010).
Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines.
Majewski J., Foulkes W.D.
BMC Med. Genomics 4:75.1-75.13(2011).
Proteomic portrait of human breast cancer progression identifies novel prognostic markers.
Geiger T., Madden S.F., Gallagher W.M., Cox J., Mann M.
Cancer Res. 72:2428-2439(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Essential gene profiles in breast, pancreatic, and ovarian cancer cells.
Rottapel R., Neel B.G., Moffat J.
Cancer Discov. 2:172-189(2012).
Molecular characterisation of cell line models for triple-negative breast cancers.
Reis-Filho J.S., Tutt A.
BMC Genomics 13:619.1-619.14(2012).
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Martens J.W.M.
Breast Cancer Res. 15:R33.1-R33.17(2013).
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
McCormick F., Gray J.W.
Cancer Cell 24:450-465(2013).
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.
Breast Cancer Res. Treat. 142:237-255(2013).
Modeling precision treatment of breast cancer.";
Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
Genome Biol. 14:R110.1-R110.14(2013).
A comprehensive transcriptional portrait of human cancer cell lines.
Settleman J., Seshagiri S., Zhang Z.-M.
Nat. Biotechnol. 33:306-312(2015).
Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation.
Bassani-Sternberg M., Pletscher-Frankild S., Jensen L.J., Mann M.
Mol. Cell. Proteomics 14:658-673(2015).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
The proteomic landscape of triple-negative breast cancer.";
Irie H.Y., Lee S.-I., Blau C.A., Villen J.
Cell Rep. 11:630-644(2015).
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
OncoImmunology 3:e954893.1-e954893.12(2014).